Last reviewed · How we verify
anle138b
At a glance
| Generic name | anle138b |
|---|---|
| Sponsor | MODAG GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy (PHASE2)
- A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b) (PHASE1)
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease (PHASE1)
- A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anle138b CI brief — competitive landscape report
- anle138b updates RSS · CI watch RSS
- MODAG GmbH portfolio CI